Review Volume 1, Issue 3 pp 281—288
Validation of anti-aging drugs by treating age-related diseases
- 1 Cancer Center, Ordway Research Institute, Albany, NY 12208, USA
received: September 20, 2008 ; accepted: March 28, 2009 ; published: March 28, 2009 ;https://doi.org/10.18632/aging.100034
How to Cite
Humans die from age-related diseases, which are deadly manifestations of the aging process. In order to extend life span, an anti-aging drug must delay age-related diseases. All together age-related diseases are the best biomarker of aging. Once a drug is used for treatment of any one chronic disease, its effect against other diseases (atherosclerosis, cancer, prostate enlargement, osteoporosis, insulin resistance, Alzheimer's and Parkinson's diseases, age-related macular degeneration) may be evaluated in the same group of patients. If the group is large, then the anti-aging effect could be validated in a couple of years. Startlingly, retrospective analysis of clinical and preclinical data reveals four potential anti-aging modalities.